Regenerative Medicine Market Size 6.49 Bn by 2027 | CAGR of 9.3%
www.emergenresearch.com
external-link

Regenerative medicine market is estimated to grow at a CAGR of 9.3% from USD 3.05 billion in 2019 to USD 6.49 billion in 2027. A strong product pipeline and government and private investment to support research are expected to fuel growth in clinical trials.

The Global Regenerative Medicine Market is projected to reach USD 6.49 billion in 2027. The treatment of specific indications and chronic conditions is expected to have significant effects on healthcare. Therefore, a high prevalence, combined with increasing global geriatric population and cancer, neurodegenerative, orthopedic and other aging-related disorders drive market growth. In addition, the increasing prevalence of genetic diseases inherited in the field of biotechnology is expected to increase demand.

The variety of applications, as well as major advances in tissue engineering, stem cells, gene therapy, drug discovery and nanotechnology are expected to give the regenerative medicine field considerable attention. 3D printing, for example, is favored rather than scaffolding with stem cells to restore organic structure and functional properties.

Owing to the availability of various drugs and their use in simple chronical healing of the wounds, dermatology is expected to have the largest market share in revenue in 2018. Due to the existence of a large pipeline of regenerative drugs for treatment of carcinoma, oncology, on the other hand, is expected to grow over the forecast timeframe in the fastest CAGR.

North America had the largest share of revenue of regenerative medicines in 2019 and its dominant position is expected to continue in the foerthcoming period. A large number of universities and academic organizations are expected to fuel development by exploring various stem cell-based regenerative approaches.

Further key findings from the report suggest

CVD’s incidence in the coming years will dramatically increase with increased use of sedentary lifestyles, a changing eating patterns and many persons with major CVD risk factors. The use of primary cell-based therapies and developments in the stem cell and progenitor cell therapies has contributed to therapeutics dominating the consumer segments. The most important proportion of this category is obtained by primary cell-based therapies in dermatological, musculoskeletal and dental applications. Stem cell and progenitor-cell-based therapies are expected to show significant growth as stem cell research expenditures and growing numbers of stem cell banks increase. Key players are providing consulting services that lead to profitable service segment growth, due to increased R&D and clinical trials. The most rapidly adoption of the cell-based approaches to healthcare and the emergence of key operators is expected to be seen in Asia Pacific during the forecast period. In March 2018, Hitachi Chemical signed an agreement for the clinical manufacturing of regenerative medicinal products produced by companies in the respective Japanese and US markets with the Daiichi Sankyo and the SanBio Group. Key players in the market include Integra LifeSciences Corporation, Astellas Pharma Inc., Corline Biomedical AB, COOK BIOTECH, INC., Bayer BV, Abbott, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., and Merck & Co., Inc., among others. To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/regenerative-medicine-market

For the purpose of this report, Emergen Research has segmented into the global Regenerative Medicine Market on the basis of Product, Therapeutic Category, Application, and region:

Product Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027) Therapeutics Tools Banks Services Therapeutic Category Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027) Dermatology Musculoskeletal Immunology & Inflammation Oncology Cardiovascular Ophthalmology Others Application Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027) Musculoskeletal Disorders Wound Care Oncology Ocular Disorders Diabetes Regional Outlook (Revenue: USD Billion; Volume: Million Tons; 2017-2027) North America U.S. Canada Europe UK Germany France BENELUX Asia Pacific China Japan South Korea Rest of APAC Latin America Brazil Rest of LATAM MEA Saudi Arabia UAE Rest of MEA

Stammtisch Hallertau
!main

    Stammtisch Hallertau

    • 0 users online
    • 1 user / day
    • 2 users / week
    • 2 users / month
    • 3 users / 6 months
    • 12 subscribers
    • 9 Posts
    • 1 Comment
    • Modlog